Skip to main content

Ophthalmology Retina

ISSN: 2468-6530

Visit Journal website

Datasets associated with articles published in Ophthalmology Retina

Filter Results
1970
2024
1970 2024
9 results
  • Data for: Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular AMD Patients: A “Real World” Analysis in 49,485 Eyes
    Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular AMD Patients
    • Dataset
  • Data for: Post-Intravitreal Injection Ciprofloxacin and Conjunctival Flora Resistance
    Data collected for conjunctival swab study from October 2014 to May 2016 including collection method, subject number, eye, date, indication, number of injections in the last 6 months, 12 months, antibiotic used, age of patient, gender, organisms cultured and antibiotics to which those organisms were found resistant.
    • Dataset
  • Data for: Characterization of Choroidal Nevi with Dark Field Infrared Scanning Laser Ophthalmoscopy
    Dark field scanning laser ophthalmoscopy, en face optical coherence tomography and color fundus photography images of patients with choroidal nevi and healthy volunteers which were used in the analysis of the sensitivity and specificity of all three methods and for measurements of the nevi area.
    • Dataset
  • Data for: Ultrasound Biomicroscopic Analysis of the Sutureless Scleral Fixated Intraocular Lens
    see attached files
    • Dataset
  • Data for: “Real-World” Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States
    Excel Spreadsheet
    • Dataset
  • Data for: Long-Term Safety and Efficacy of Limited Vitrectomy for Vision Degrading Vitreopathy from Vitreous Floaters
    Demographic and clinical research data on vitreous structure and visual function from 195 subjects undergoing limited vitrectomy to treat Vision Degrading Vitreopathy from vitreous floaters.
    • Dataset
  • Data for: “Real World” Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular AMD in the United States: The Relationship Between Loss to Follow-up and Visual Outcomes
    “Real World” Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular AMD in the United States Purpose: “Real world” visual outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular AMD (nAMD) have been reported in cohorts outside of the United States (U.S.). This study sought to assess the relationship between presenting visual acuity (VA) and visual outcomes, as well as the potential impact of loss to follow-up, in “real world” anti-VEGF treated nAMD patients from the U.S. Design: Retrospective study of aggregated, longitudinal electronic medical records (EMR) from a geographically diverse sample of U.S. retina specialists (Vestrum Health Retina Database, Vestrum Health, LLC). Subjects, Participants, and/or Controls: Inclusion criteria were: a diagnosis of nAMD, no previous treatment, and at least 3 monthly anti-VEGF injections in the first 4 months from diagnosis between January 2011 and July 2013. Methods: To model loss to follow-up, mutually exclusive cohorts of nAMD patients with loss to follow up after specific time points of 6 and 12 months (no follow-up beyond) were compared to a separate cohort of patients who completed 24 months of follow-up, ending prior to July 2015 (n=2,213). Main Outcome Measure: VA outcomes were assessed on each cohort as a whole, with additional stratification by baseline VA. Results: The 6-, 12-, and 24-month cohorts each received a mean of 5.4, 7.3, and 12.1 injections, and showed no change, no change, and mean change of +3.1 letters from baseline (95% confidence interval 1.8 - 4.4, p < 0.01) respectively. When stratified by baseline VA, nearly all groups lose VA at their respective follow-up periods, except for those with baseline VA of 20/200 or worse. Conclusion: “Real world” nAMD patients in the U.S. receive fewer anti-VEGF injections and experience worse visual outcomes compared to patients in randomized clinical trials, consistent with non-U.S. studies. Compared to patients with worse VA at presentation, patients with better VA at presentation tend to be particularly vulnerable to vision loss. Compared to other patients, those ultimately lost to follow-up have worse visual outcomes at, or prior to, their final visit, suggesting that loss to follow-up can lead to overestimation of visual outcomes in clinical studies of nAMD.
    • Dataset
  • Data Files for: Pedersen et. al. The cone photoreceptor mosaic in aniridia: within-family phenotype-genotype discordance
    In this descriptive case-control study we used high-resolution in-vivo retinal imaging to investigate within-family variability in macular retinal layer thicknesses, cone photoreceptor density and mosaic regularity in PAX6-related aniridia compared with normal controls.Data Files:(i) OCT measurements of retinal layer thicknesses from seven persons with congenital aniridia(ii) Measurements of the cone photoreceptor mosaic and density for five persons with PAX6-related congenital aniridia(iii) Inter- and intra-rater repeated cone counting for the five persons with aniridia
    • Dataset
  • Data Files for: Pedersen et. al. The cone photoreceptor mosaic in aniridia: within-family phenotype-genotype discordance
    In this descriptive case-control study we used high-resolution in-vivo retinal imaging to investigate within-family variability in macular retinal layer thicknesses, cone photoreceptor density and mosaic regularity in PAX6-related aniridia compared with normal controls.Data Files:(i) OCT measurements of retinal layer thicknesses from seven persons with congenital aniridia(ii) Measurements of the cone photoreceptor mosaic and density for five persons with PAX6-related congenital aniridia(iii) Inter- and intra-rater repeated cone counting for the five persons with aniridia
    • Dataset